In this study, we present data showing that inhibiting VSIG4 by a monoclonal antibody or by siRNA relieves VSIG4-mediated macrophage suppression and leads to repolarizing TAMs to an inflammatory phenotype capable of coordinating an anti-tumor immune response in preclinical settings. This evidence concerns the gene VSIG4 and neoplasm.